Overexpression of miR-200b-3p in Menstrual Blood-Derived Mesenchymal Stem Cells from Endometriosis Women

被引:0
作者
Rafael Zucco de Oliveira
Fabiana de Oliveira Buono
Ana Clara Lagazzi Cressoni
Letícia Bruna Corrêa Penariol
Cristiana Carolina Padovan
Patricia Aparecida Tozetti
Omero Benedito Poli-Neto
Rui Alberto Ferriani
Maristela Delgado Orellana
Júlio Cesar Rosa-e-Silva
Juliana Meola
机构
[1] University of São Paulo,Division of Human Reproduction, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School
[2] University of São Paulo,Laboratory for Translational Data Science, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School
[3] National Institute of Hormones and Women’s Health (Hormona),Center for Cell Therapy and Reginal Blood Center
[4] CNPq,undefined
[5] University of São Paulo,undefined
来源
Reproductive Sciences | 2022年 / 29卷
关键词
miR-200b-3p; Endometriosis; MenSCs; Menstrual blood; RT-qPCR;
D O I
暂无
中图分类号
学科分类号
摘要
The key relationship between Sampson’s theory and the presence of mesenchymal stem cells in the menstrual flow (MenSCs), as well as the changes in post-transcriptional regulatory processes as actors in the etiopathogenesis of endometriosis, are poorly understood. No study to date has investigated the imbalance of miRNAs in MenSCs related to the disease. Thus, through literature and in silico analyses, we selected four predicted miRNAs as regulators of EGR1, SNAI1, NR4A1, NR4A2, ID1, LAMC3, and FOSB involved in pathways of apoptosis, angiogenesis, response to steroid hormones, migration, differentiation, and cell proliferation. These genes are frequently overexpressed in the endometriosis condition in our group studies. They were the trigger for the miRNAs search. Therefore, a case–control study was conducted with MenSCs of women with and without endometriosis (ten samples per group). Crossing information obtained from the STRING, PubMed, miRPathDB, miRWalk, and DIANA TOOLS databases, we chose to explore the expression of miR-21-5p, miR-100-5p, miR-143-3p, and miR-200b-3p by RT-qPCR. We found an upregulation of the miR-200b-3p in endometriosis MenSCs (P = 0.0207), with a 7.93-fold change (ratio of geometric means) compared to control. Overexpression of miR-200b has been associated with increased cell proliferation, stemness, and accentuated mesenchymal-epithelial transition process in eutopic endometrium of endometriosis. We believe that dysregulated miR-200b-3p may establish primary changes in the MenSCs, thus favoring tissue implantation at the ectopic site.
引用
收藏
页码:734 / 742
页数:8
相关论文
共 175 条
  • [1] Sourial S(2014)Theories on the pathogenesis of endometriosis Int J Reprod Med 2014 179515-95
  • [2] Tempest N(2019)The pathogenesis of endometriosis: molecular and cell biology insights Int J Mol Sci 20 5615-469
  • [3] Hapangama DK(2020)The origin and pathogenesis of endometriosis Annu Rev Pathol 15 71-918
  • [4] Laganà AS(1927)Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity Am J Obstet Gynecol 14 422-115
  • [5] Garzon S(2014)Menstrual blood-derived stromal stem cells from women with and without endometriosis reveal different phenotypic and functional characteristics Mol Hum Reprod 20 905-38
  • [6] Götte M(2008)Stem cells and the pathogenesis of endometriosis Ann N Y Acad Sci 1127 106-1159
  • [7] Wang Y(2018)Endometrial stem/progenitor cells and their role in the pathogenesis of endometriosis Best Pract Res: Clin Obstet Gynaecol 50 27-320
  • [8] Nicholes K(2020)The role of endometrial stem cells in the pathogenesis of endometriosis and their application to its early diagnosis Biol Reprod 102 1153-2102
  • [9] Shih I-M(2020)Transcriptome meta-analysis reveals differences of immune profile between eutopic endometrium from stage I-II and III-IV endometriosis independently of hormonal milieu Sci Rep 10 313-6
  • [10] Sampson JA(2021)Eutopic endometrium from women with endometriosis and chlamydial endometritis share immunological cell types and DNA repair imbalance: a transcriptome meta-analytical perspective J Reprod Immunol 145 103307-2029